History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio.
Matt DiLallo, The Motley FoolSat, October 10, 2026 at 6:35 PM UTC
0
Image source: The Motley Fool.Key Points -
Abbott has grown its earnings per share at a nearly 10% compound annual rate over the past decade.
Its stock price could more than double by 2036 using a more conservative 8% growth rate.
Abbott also pays a high-yielding, steadily rising dividend, adding to its total return.
10 stocks we like better than Abbott Laboratories ›
Abbott(NYSE:ABT) currently trades for less than $100 a share. A conservative base-case model suggests the healthcare stock could be worth around $210 per share a decade from now. The best part is that doubling doesn't require anything close to optimistic assumptions; it's grounded in Abbott's recent history.
This high upside potential from a low-risk, high-quality dividend stock is why I just added Abbott to my portfolio this week.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
A history lesson
In 2016, Abbott generated nearly $21 billion in sales and $2.20 per share of adjusted earnings. This year, the healthcare company expects to report about $47 billion in sales and $5.53 of earnings at the mid-point of its current guidance range. That's a 9.7% compound annual earnings-per-share growth rate over the past decade.
Acquisitions helped Abbott deliver a nearly double-digit compound annual earnings growth rate over the past decade. In 2017, it bought both St. Jude Medical and Alere for $25 billion and $5.8 billion, respectively. These deals enhanced its operations and earnings (both were accretive in the first full year). The company also bought Exact Sciences earlier this year for $21 billion, a move that is boosting its 2026 results.
Abbot's share price has followed its revenue and earnings higher. It's up 130% over the last 10 years (8.7% annualized total return). That doesn't include dividends. Add in Abbott's steadily rising dividend, and the total return with dividends reinvested is more than 175% (10.7% annualized). Abbott has increased its dividend for 54 consecutive years, qualifying it as a Dividend King (a company with 50 or more years of annual dividend increase).
The math to $210 (or more) by 2036
I considered several scenarios when evaluating Abbott for my portfolio. I settled on a base case in which Abbott Labs grows its earnings at a 8% compound annual rate over the next decade. I chose that more conservative rate because acquisitions played a meaningful role in driving growth over the past 10 years. Under this conservative scenario, Abbott's earnings would grow to about $11.93 per share by 2036. Assuming a 17.5x valuation multiple (Abbott currently trades at about 18x forward earnings), that would put its share price at around $210.
That doesn't include Abbott's dividend, which currently yields 2.5%, more than double the S&P 500's level of around 1%. The company would likely continue to grow that payout at a mid-to-high single-digit annual rate (it hiked its dividend by 6.8% this year and has grown it by 70% since 2020).
Why I just bought Abbott stock
Abbott fits perfectly with my current financial plan. I'm seeking more resilient, income-focused holdings to set me up for an early retirement if AI ever disrupts my job. Abbott checks every box. It provides durable, steadily rising dividend income backed by a diversified portfolio of healthcare technologies, including diagnostics, medical devices, nutritionals, and branded generic medicines. It's the exact type of defensive holding I'm seeking to provide more ballast.
Advertisement
Further, Abbott provides a strong defense without giving up any offensive upside. With a 2.5% dividend yield and earnings growing conservatively at 8% annually, Abbott could generate double-digit annual returns over the next 10 years. That strong return doesn't require any large acquisitions to boost its results. Meanwhile, faster acquisition-driven growth would position Abbott to generate even higher returns. For example, a 9%+ earnings growth rate with a slightly higher valuation multiple would push the stock price toward $250 by 2036.
I also like that the downside risk is low. The company does have risks, including integrating Exact Sciences and managing the heavier debt load from that all-cash deal. However, even if growth slowed and its valuation multiple continued to fall, Abbott should still be worth more in a decade than it is today while also providing a steadily rising income stream.
Abbott's history says it has a bright future
Abbott has historically grown its earnings at a nearly 10% compound annual rate over the last decade. It doesn't need to grow that fast in the future to deliver a very favorable outcome for shareholders, as 8% annual earnings-per-share growth could double its share price by 2036, with its steadily rising, high-yielding dividend adding to the total return. That's exactly the lower-risk, higher-upside investment I'm seeking to make these days, which is why I just added Abbott to my portfolio. I expect to build this position into a meaningful part of my financial independence plan.
Should you buy stock in Abbott Laboratories right now?
Before you buy stock in Abbott Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,408,822!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 10, 2026.
Matt DiLallo has positions in Abbott Laboratories. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
Source: “AOL Money”
